IGHE and allergic disease: A key advantage of the peptides lies in their smaller size; i.e., molecules that are of insufficient length to trigger cross-linking of IgE on mast cells and basophils, may provide an advantage by potentially reducing the risk of IgE-mediated allergic reactions such as asthma, urticaria, or anaphylaxis [16–22].